Table 2.
Baseline characteristics according to electrical storm at presentation
| Characteristic | Overall study population ((N = 259) | No electrical storm (N = 227) | Electrical storm (N = 32) | P-value for comparison across groups |
|---|---|---|---|---|
| Age (years) | 68.6 ± 8.1 | 68.4 | 70.4 ± 7.7 | 0.20 |
| Male sex, no. (%) | 241 (93.1%) | 212 (93.4%) | 29 (90.6%) | 0.56 |
| Previous PCI, no. (%) | 112 (43.2%) | 99 (43.6%) | 13 (40.6%) | 0.75 |
| Previous CABG, no. (%) | 118 (45.6%) | 102 (44.9%) | 16 (50%) | 0.59 |
| Diabetes, no. (%) | 77 (29.7%) | 68 (30.0%) | 9 (28.1%) | 0.83 |
| Hypertension, no. (%) | 180 (69.5%) | 161 (70.9%) | 19 (59.4%) | 0.18 |
| Chronic kidney disease, no. (%) | 49 (18.9%) | 43 (18.9%) | 6 (18.8%) | 0.98 |
| Atrial fibrillation/flutter, no. (%) | 99 (38.2%) | 88 (38.8%) | 11 (34.4%) | 0.63 |
| NYHA class, no. (%) | ||||
| I | 61 (23.6%) | 52 (22.9%) | 9 (28.1%) | 0.74 |
| II | 137 (52.9%) | 122 (53.7%) | 15 (46.9%) | |
| III | 61 (23.6%) | 53 (23.3%) | 8 (25%) | |
| Ejection fraction (%) | 28.8 ± 10 | 28.4 | 31.9 ± 11.1 | 0.17 |
| CRT defibrillator, no. (%) | 51 (19.7%) | 45 (19.8%) | 6 (18.8%) | 0.89 |
| Antiarrhythmic drug at qualification, no. (%) | ||||
| Amiodarone | 169 (65.3%) | 153 (67.4%) | 16 (50%) | 0.05 |
| Other medication | 90 (34.7%) | 74 (32.6%) | 16 (51.6%) | |
| NT-proBNP (pg/mL) | 548 (274–1270) | 552 (278–1199) | 437 (217–1598) | 0.28 |
ATP, anti-tachycardia pacing; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator; NTproBNP, N-terminal pro-hormone brain natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; VT, ventricular tachycardia.